Declaration of Voting Results & Voting Rights Announcements • Feb 6, 2018
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
(Article 223-16 of General Regulation of the French financial markets authority)
ISIN code: FR0010425595
| Date | Total number of shares in the capital |
Total number of voting rights |
|---|---|---|
| 01/31/2018 | 35,959,462 | 41,114,862 |
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.
Jennifer Moore, VP of Communications, 917-580-1088, [email protected] Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [email protected]
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [email protected]
This press release contains "forward-looking" statements that are based on our management's current expectations and assumptions and on information currently
available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forwardlooking statements, even if new information becomes available in the future.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.